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Abstract
Background: Widespread increases in caesarean section (CS) rates have sparked concerns about risks to mothers
and infants and rising healthcare costs. A multicentre, two-arm, cluster-randomized trial in Quebec, Canada assessed
whether an audit and feedback intervention targeting health professionals would reduce CS rates for pregnant
women compared to usual care, and concluded that it reduced CS rates without adverse effects on maternal or
neonatal health. The effect was statistically significant but clinically small. We assessed cost-effectiveness to inform
scale-up decisions.
Methods: A prospective economic evaluation was undertaken using individual patient data from the Quality of
Care, Obstetrics Risk Management, and Mode of Delivery (QUARISMA) trial (April 2008 to October 2011). Analyses
took a healthcare payer perspective. The time horizon captured hospital-based costs and clinical events for mothers
and neonates from labour onset to 3 months postpartum. Resource use was identified and measured from patient
charts and valued using standardized government sources. We estimated the changes in CS rates and costs for the
intervention group (versus controls) between the baseline and post-intervention periods. We examined
heterogeneity between clinical subgroups of high-risk versus low-risk pregnancies and estimated the joint
uncertainty in cost-effectiveness over 20,000 trial simulations. We decomposed costs to identify drivers of change.
Results: The intervention group experienced per-patient reductions of 0.005 CS (95% confidence interval (CI): −0.
015 to 0.004, P = 0.09) and $180 (95% CI: −$277 to − $83, P < 0.001). Women with low-risk pregnancies experienced
statistically significant reductions in CS rates and costs; changes for the high-risk subgroup were not significant. The
intervention was “dominant” (effective in reducing CS and less costly than usual care) in 86.08% of simulations. It
reduced costs in 99.99% of simulations. Cost reductions were driven by lower rates of neonatal complications in the
intervention group (−$190, 95% CI: −$255 to − $125, P < 0.001). Given 88,000 annual provincial births, a similar
intervention could save $15.8 million (range: $7.3 to $24.4 million) in Quebec annually.
Conclusions: From a healthcare payer perspective, a multifaceted intervention involving audits and feedback
resulted in a small reduction in caesarean deliveries and important cost savings. Cost reductions are consistent with
improved quality of care in intervention group hospitals.
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Background
The use of caesarean sections has increased to unprece-
dented levels worldwide; 18.6% of global and 32.3% of
North American births now occur by caesarean section
[1]. With the exception of the African region, where cae-
sarean section rates remain low, substantial increases in
caesarean deliveries have been documented in all global
regions [1]. Caesarean sections are important in reducing
maternal and perinatal mortality and morbidity when
medically justified; however, non-medically necessary cae-
sareans have no documented benefit [2]. In many jurisdic-
tions, caesarean section rates in excess of recommended
thresholds have sparked concerns about potential risks
to mothers and infants and escalating healthcare costs
[1, 3, 4]. Evidence concerning effective approaches to re-
duce unnecessary caesareans is currently limited [3, 5].
The Quality of Care, Obstetrics Risk Management,
and Mode of Delivery (QUARISMA) study was a
cluster-randomized controlled trial conducted from
2008 to 2011 in 32 hospitals in Quebec, Canada [6]. The
trial assessed whether a multifaceted audit and feedback
intervention targeting health professionals involved in
labour, delivery, and postpartum care would reduce cae-
sarean section rates as compared to usual care for preg-
nant women [6]. The idea motivating the QUARISMA
trial was that an effective knowledge translation inter-
vention could improve adherence to clinical practice
guidelines and quality of care, thereby reducing unneces-
sary caesareans and optimizing resource use.
The main trial analysis found a statistically significant but
clinically small reduction in caesarean sections (adjusted
absolute risk difference of −1.8% (95% CI: −3.8 to −0.2,
P = 0.04) with no adverse effects on maternal or neonatal
health outcomes [6]. The reduction in caesareans was ob-
served among women with low-risk pregnancies but not
among women with high-risk pregnancies [6]. Although re-
sources required to deliver the intervention are modest, the
anticipated magnitude of clinical benefit is small, leaving
unanswered questions about whether the intervention
should be offered at scale. A cost-effectiveness analysis is
required to complete information from the trial and enable
decision makers to interpret results for policy and practice.
We conducted a cost-effectiveness analysis of the
QUARISMA trial using individual patient data. Our pri-
mary objective was to compare the impact on caesarean de-
livery rates and costs of a multifaceted audit and feedback
intervention targeting health professionals versus usual care
for pregnant women. Subgroup analyses examined cost-
effectiveness in high-risk versus low-risk pregnancies, the
clinical subgroups established a priori for the trial.
Methods
The QUARISMA trial was conducted in the province of
Quebec, Canada. In 2014, Quebec’s population was 8.2
million, and life expectancy at birth was 79 for males
and 83 for females [7]. Gross domestic product per
capita measured in US dollar purchasing power parity
was $36,216 in 2013 [8]. The QUARISMA economic
evaluation adopted the perspective of the publicly
funded healthcare system in Quebec. Analysis of effects
focused on the primary hypothesized trial outcome of
reduction in caesarean sections, while cost analysis ex-
amined direct costs to the public healthcare system. Cost
variables capture the full spectrum of resource use re-
lated to labour and delivery from hospital admission for
labour until 3 months postpartum. As delivery mode
(caesarean or vaginal) was the primary trial endpoint, a
short-term hospital stay is sufficient to capture all mean-
ingful differences in costs and clinical outcomes between
intervention and control arms. Costs and health out-
comes were discounted at an annual rate of 0% due to
the short (<1 year) period for results assessment [9, 10].
All participating hospital centres granted research eth-
ics approval for the trial.
Trial overview
Details of the QUARISMA trial have been reported [6].
Briefly, QUARISMA employed a cluster-randomized de-
sign with a 1:1 allocation ratio. Clusters were 32 public
hospitals in the province of Quebec, Canada. Hospitals
were stratified by level of care and assigned to either the
intervention or control group using computer-generated
blocked randomization within each stratum. Hospital
centres were eligible to participate if they had at least
300 deliveries in the year prior to study initiation, a cae-
sarean section rate of at least 17%, and no concurrent
program to reduce caesareans. Based on these criteria,
40 hospitals were eligible, 38 agreed to participate, and
32 were randomly selected for inclusion. All women
who gave birth at a participating hospital during the
study period and whose newborns met criteria related to
gestational age (≥24 weeks) and birth weight (≥500 g)
were included in the analysis.
The study comprised three phases: a 1-year pre-
intervention (baseline) period, a 1.5-year intervention
period, and a 1-year post-intervention period. The base-
line period involved onsite training and capacity building
to improve caesarean delivery and intrapartum care.
During the 1.5-year intervention period, hospital audit
committees implemented four 3-month audit cycles
using local data to assess the appropriateness of caesar-
ean delivery, engage in collective learning, provide feed-
back to clinicians, and implement best practices based
on the results. Analyses for the main trial and the eco-
nomic evaluation compared outcomes in the 1-year
baseline period (1 April 2008 to 31 March 2009) to those
in the 1-year post-intervention period (1 November 2010
to 31 October 2011). The QUARISMA trial captured
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more than 65% of all deliveries in Quebec province during
the study period [11]. No hospital or woman was lost to
follow-up.
Sample size
QUARISMA was designed and powered to detect differ-
ences between treatment groups in the primary clinical
endpoint (caesarean sections averted). Sample size cal-
culations were not designed to test cost-effectiveness
hypotheses.
Effects
We recorded clinical events from patient charts. Trained
data collectors extracted data concerning caesarean or
vaginal delivery as well as secondary outcomes including
major and minor maternal complications and major and
minor neonatal complications [6]. Trained research
nurses or medical archivists abstracted in-hospital data
from the medical records of mothers and newborns
3 months after delivery. Data collectors were aware of
randomization assignments but were not involved in out-
comes assessment. Given the nature of the clinical condi-
tion and the short time horizon, we did not include
preference-based measures of health-related quality of life.
Resource use and costs
We considered resource use and costs associated with
delivery and complications recorded in the QUARISMA
trial (Additional file 1: Section 3; Table S1) [6]. Medical
procedure costs (Additional file 1: Table S2 and Table
S3) were calculated as the sum of inpatient (hospital)
costs and physician fees. For all trial participants con-
tributing data to either the baseline or post-intervention
period, we used inpatient chart data to identify clinical
events generating resource use. To estimate inpatient
procedure costs, we applied unit costs from the 2013
Canadian Institute for Health Information (CIHI) Patient
Cost Estimator (PCE) for the jurisdiction of Quebec to
resource use categories [12]. Published annually by the
Canadian government, PCE costs represent the product
of the costs of a standard hospital stay in a specific juris-
diction multiplied by a resource intensity weight reflect-
ing resource use for a specific case mix and age group
[12]. The 2013 PCE release includes 2010–2011 financial
information [12], which corresponds to the QUARISMA
post-intervention period. PCE costs exclude physician
fees, which were taken from Canada’s National Physician
Database (NPD), 2011–2012 [13]. Total costs also in-
cluded resource requirements and costs associated with
delivery of the QUARISMA intervention (Additional file
1: Table S4), which were estimated directly from QUAR-
ISMA trial records. Protocol-driven costs were excluded
[9]. All costs are reported in 2013 Canadian dollars. In
2013, one US dollar was worth on average 1.03 Canadian
dollars [14].
Statistical analysis
Analyses for the QUARISMA economic evaluation were
based on the intention-to-treat principle and carried for-
ward strategies from the main trial analysis [6]. We
adopted a variant of the difference-in-differences ap-
proach to estimate the intervention effect while control-
ling for unobserved characteristics of individual patients
or program placement in hospitals that might lead to se-
lection bias [15]. Specifically, to assess intervention im-
pact, we studied changes in caesarean delivery rates and
costs in the two study groups between the 1-year base-
line period and the 1-year post-intervention period using
adjusted regression coefficients (with their 95% confi-
dence intervals) for the interaction between group
(intervention or control) and time period (post-interven-
tion or baseline) [6, 16].
Main analysis
We modelled costs and effects jointly using bivariate
multilevel linear models that explicitly recognize poten-
tial correlations between the bivariate outcomes (caesar-
ean sections and costs) at individual and cluster
(hospital) levels. In our models, individual patients (level 1)
were assumed to be nested within hospitals (level 2), and
correlations were estimated at both hierarchical levels. We
used cluster-level random effects to handle clustering of
observations within hospitals [17, 18]. The analysis in-
cluded all trial participants. Crude models studied the
intervention effect by estimating the interaction between
study group and time period. Adjusted models estimated
the same interaction term while including additional base-
line covariates (pregnancy risk, parity, current smoking,
birth weight, and hospital type) used in the QUARISMA
trial analysis [6]. Models were estimated by restricted un-
biased iterative generalized least-squares estimation imple-
mented in MLwiN (version 2.35) [19] within Stata 14.1
using the runmlwin [20] command.
We had intended to calculate the incremental cost-
effectiveness ratio (ICER) statistic as the ratio of add-
itional costs per additional caesarean sections averted.
However, interpretation is problematic when ICER esti-
mates are negative, as in this case where the intervention
reduces costs [21]. Incremental costs and effects are
therefore presented separately.
Uncertainty and heterogeneity of the cost-effectiveness
measures
We applied Bayesian Markov chain Monte Carlo
methods to the bivariate multilevel linear models used
in the main analysis to ascertain the joint uncertainty of
the estimands, incremental costs, and effects [22]. The
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posterior distributions of the incremental costs and effects
were given by 20,000 iterations of the Markov chains after
a burn-in of 5000 iterations. We used cost-effectiveness
planes plotting the values of incremental costs and effects
stored in the Markov chains to present the joint uncer-
tainty of the estimands. To explore potential heterogeneity
in the results, we prospectively planned to repeat all ana-
lyses over patient risk subgroups [21].
Other analyses
We adapted the bivariate multilevel linear models from
the main analysis to consider two further issues. (1)
NPD estimates for physician billings are uncertain [13]
and can substantially influence total costs. We prospect-
ively planned sensitivity analyses using alternative phys-
ician fee estimates from the Quebec medical specialists
billing manual [23]. (2) To gain insight into cost drivers,
we decomposed total costs into costs associated with de-
livery, maternal complications, and neonatal complica-
tions. Costs were grouped into these three categories
because statistical power was insufficient to examine
cost differences on a per-complication basis. Analyses of
cost components were empirically motivated.
An independent team not involved in the main trial
analysis conducted the economic analysis. All reported P
values are two-sided. P values lower than 0.05 were con-
sidered statistically significant. Additional file 1: Section




All (100%) of the 105,351 women who delivered in the
baseline or post-intervention period were included in
the QUARISMA main trial analysis [6] and the eco-
nomic evaluation. Analysis of baseline hospital, cost, and
patient characteristics (Additional file 1: Table S5) re-
vealed no significant differences between study groups,
with the exception of maternal parity, which was included
as a covariate in the adjusted analyses.
Incremental costs and effects
Table 1 presents main analysis results concerning the incre-
mental change in effects and costs due to the QUARISMA
intervention. Analyses including all patients showed a small
non-significant reduction in caesareans in the intervention
group as compared to controls and an important reduction
in costs, yielding adjusted estimates (Table 1, Model 2) of a
per-patient reduction of 0.005 caesarean sections (95%
confidence interval (CI): –0.015 to 0.004, P = 0.09) and
$180 saved (95% CI: −$277 to − $83, P < 0.001). Patterns
differed by patient risk. Women with low-risk pregnancies
experienced larger, statistically significant reductions in
caesarean sections and costs. Women with high-risk
pregnancies experienced a small, non-significant increase in
caesarean sections and a non-significant reduction in costs.
Sensitivity analyses using alternative cost estimates pre-
dicted lower estimated savings but similar conclusions
(Additional file 1: Table S6).
Uncertainty of incremental costs and effects
Figures 1 and 2 present the joint uncertainties in cost
and effectiveness estimates from the Bayesian Markov
chain Monte Carlo analyses on the cost-effectiveness
plane. Analyses including all patients (Fig. 1) revealed
that the intervention reduced caesarean sections and
costs in 86.01% of the Monte Carlo iterations, and re-
duced costs in 99.99% of iterations. For women with
low-risk (high-risk) pregnancies (Fig. 2), the intervention
reduced caesarean sections in 99.81% (15.97%) of the it-
erations, reduced costs in 99.98% (90.36%), and reduced
both outcomes in 99.79% (15.24%). Sensitivity analyses
using alternative cost estimates generated similar results
(Additional file 1: Figure S1 and Figure S2).
Cost subcategories
Table 2 presents changes in per-patient costs by subcat-
egories of delivery costs, maternal complications, and
neonatal complications. Findings suggest that the inter-
vention to reduce caesarean sections resulted in im-
proved quality along the continuum of care. Adjusted
analyses including all patients revealed that the major
driver of cost reductions was management of neonatal
complications (−$190, 95% CI: −$255 to− $125, P < 0.001),
which were less frequent in the intervention group [6].
Reductions in management costs for neonatal cardiopul-
monary complications were especially important (−$150,
95% CI: −$197 to − $103, P < 0.001); costs for other neo-
natal complications were also reduced (−$41, 95% CI: −$80
to − $1, P < 0.047). Results using alternative cost assump-
tions were similar (Additional file 1: Table S7).
Discussion
The QUARISMA trial found that an intervention involv-
ing clinical audits, feedback, and implementation of best
practices resulted in a statistically significant but small
reduction in caesarean sections without adverse effects
on maternal or neonatal outcomes [6]. In this economic
evaluation conducted alongside the main trial, the ana-
lysis including all trial participants found that the inter-
vention also conferred significant average cost savings of
$180 (95% CI: $83–277) per patient, equivalent to 3.0%
(95% CI: 1.4–4.5%) of mean per-patient total costs.
Patterns differed by patient risk. Women with low-risk
pregnancies experienced statistically significant reduc-
tions in caesarean sections and costs, while women with
high-risk pregnancies did not experience significant
changes in either outcome.
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Sensitivity analyses exploring uncertainty in cost-
effectiveness estimates over 20,000 trial simulations
demonstrated that QUARISMA was the “dominant”
intervention (effective in reducing caesarean sections
and less costly than usual care) 86.08% of the time. The
intervention reduced costs 99.99% of the time. Cost sav-
ings largely reflect the reduced costs of managing neo-
natal complications, which occurred less frequently in
the intervention group [6].
Our findings are important for clinicians and policy-
makers interested in the care of pregnant women and
neonates. The QUARISMA trial tested a multifaceted
strategy involving audits and feedback to enable groups
of health professionals to improve the quality of labour
and delivery care at participating hospitals. In addition
to achieving a statistically significant but clinically small
benefit in the primary outcome of reducing caesarean
sections, QUARISMA also demonstrated benefits for a
variety of secondary clinical endpoints consistent with
improvements in the standard of care implemented in
intervention group hospitals [6]. Secondary trial out-
comes revealing statistically significant improvements
Fig. 1 Incremental cost-effectiveness of the QUARISMA intervention versus routine care. Cost-effectiveness (CE) plane for the covariate-adjusted
cost-effectiveness analysis of the QUARISMA intervention versus routine care. Incremental cost-effectiveness results were based on 20,000 Markov
chain Monte Carlo iterations including all trial participants (N = 105,351). An ellipse containing 95% of the joint posterior distribution of incremental
costs and effects is used to represent uncertainty on the CE plane. The centre of the ellipse represents the point estimate of incremental effects and
costs, i.e. a per-patient reduction of 0.005 caesarean sections and $180 saved. Percentages represent the distribution of points by quadrant
Table 1 Impact of the QUARISMA intervention on caesarean sections and total direct medical costsa, b
Model 1: BMLM (crude) Model 2: BMLM (adjusted)
Coef. (ß) Std. Err. 95% CI P value Coef. (ß) Std. Err. 95% CI P value
All participantsc (N = 105,351 patients; 32 hospitals)c
Effects (CS) −0.009 0.005 (−0.019 to 0.002) 0.096 −0.005 0.005 (−0.015 to 0.004) 0.288
Costs ($) −185 50 (−283 to −86) <0.001 −180 49 (−277 to −83) <0.001
Low-risk subgroupd (N = 49,281 patients; 32 hospitals)
Effects (CS) −0.013 0.005 (−0.023 to −0.003) 0.013 −0.014 0.005 (−0.024 to −0.004) 0.005
Costs ($) −210 63 (−334 to −87) 0.001 −226 62 (−348 to −105) <0.001
High-risk subgroupd (N = 56,070 patients; 32 hospitals)
Effects (CS) 0.009 0.008 (−0.007 to 0.024) 0.291 0.008 0.008 (−0.008 to 0.024) 0.307
Costs ($) −102 76 (−250 to 47) 0.180 −97 75 (−243 to 49) 0.193
BMLM bivariate multilevel linear model, CS caesarean section
aAll costs given in 2013 Canadian dollars = (0.94 USD) [30]
bTotal costs calculated using CIHI National Physician Database 2011–2012 physician fees for the Province of Quebec [13]
cAdjusted models for all participants included the following covariates: parity, smoking, birth weight, hospital type, and women’s risk level
dAdjusted subgroup models included the following covariates: parity, smoking, birth weight, and hospital type
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included minor neonatal morbidity (i.e. cardiopulmonary
morbidity, moderate acidosis (pH ≥7 and <7.1), minor
trauma, and neonatal infection/sepsis) and major neo-
natal morbidity (i.e. major trauma, use of invasive mech-
anical ventilation, and intrapartum and neonatal deaths)
[6]. Economic evaluation offers a framework within
which complex changes can be synthesized to aid in
policymaking. Our findings (Table 1) suggest that if a
similar intervention were to be delivered at scale in the
Province of Quebec, for an annual provincial birth
cohort of approximately 88,000 [11] and a per-patient re-
duction in caesareans of 0.005 (95% CI: −0.015 to 0.004),
one could anticipate a reduction of roughly 440 (1320
to 0) caesarean sections. For the same annual birth cohort
of 88,000 [11] and a per-patient reduction in costs of $180
(95% CI: −$277 to − $83), this translates to a cost sav-
ings of $15.8 million (range: $7.3 to $24.4 million),
achieved without increasing maternal and neonatal
morbidity and mortality.
These results have important implications for the scien-
tific literatures evaluating audit and feedback approaches
for quality improvement and non-clinical interventions to
reduce caesarean sections. The audit and feedback strat-
egy is widely used to promote quality improvement. A re-
cent Cochrane systematic review found that audit and
feedback generally leads to small but potentially important
improvements in professional practice [24], which coheres
well with the QUARISMA trial finding that the interven-
tion conferred a modest reduction in caesarean sections
[6]. Intervention impact on healthcare costs is often an
outcome of central interest for quality improvement inter-
ventions. Yet, we found only one economic evaluation of
an audit and feedback intervention based on data from a
randomized trial, published by Fretheim and colleagues in
2006 [25]. This study is a well-conducted evaluation of a
small, individually randomized trial in Norway, which
found potential cost savings due to the intervention [25].
Analytic methods have advanced considerably in the in-
terim; notably, the Fretheim and colleagues study was not
based on individual patient data.
Important studies of non-clinical interventions to re-
duce unnecessary caesareans exist [5]; however, only one
has published an economic evaluation [26]. Hollinghurst
and colleagues conducted a cost-consequences analysis
of a small, individually randomized trial of 742 pregnant
women in the UK with a prior caesarean section [26], to
evaluate two computer-based decision aids to reduce re-
peat caesarean sections [27]. One decision aid reduced
repeat caesareans and was likely cost-neutral [27].
Ours is the first economic evaluation of a non-clinical
intervention to reduce caesarean section rates based on
a cluster-randomized trial. The QUARISMA trial was
Fig. 2 Incremental cost-effectiveness of the QUARISMA intervention versus routine care, by risk subgroups. Cost-effectiveness (CE) planes for the
covariate-adjusted cost-effectiveness analysis of the QUARISMA intervention versus routine care, by patient risk subgroups. Incremental cost-effectiveness
results were based on 20,000 Markov chain Monte Carlo iterations estimated separately for low risk (N= 49,281) and high-risk (N = 56,070) trial participants.
An ellipse containing 95% of the joint posterior distribution of incremental costs and effects is used to represent uncertainty on the CE plane. The centre
of the ellipse represents the point estimate of incremental effects and costs, i.e. a per-patient reduction of 0.014 caesarean sections and $226 saved for
the low-risk subgroup, and a per-patient increase of 0.008 caesarean sections and $75 expenditure for the high-risk subgroup. Percentages represent the
distribution of points by quadrant; figures may not sum to 100 due to rounding
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well designed and implemented and captured 65% of
provincial births occurring in the trial period, plausibly
representing the general population of pregnant women in
Quebec province. Prospective data collection improved
data completeness, accuracy, and coherence, while the use
of standardized government sources for costing enhanced
generalizability. The economic analysis was based on the
intention-to-treat principle; it used complete data from in-
dividual patients and appropriate statistical methods that
accounted for clustering and correlated outcomes to de-
rive methodologically robust estimates of between-group
differences in costs and effects.
Several limitations should be considered. (1) We
assigned unit costs using Canadian government estimates
computed annually through established methodologies.
Because physician payment mechanisms in Canada are
heterogeneous, physician cost estimates are less reliable
than those for inpatient costs [13]. We repeated all ana-
lyses using an alternative data source representing billable
fees per procedure, which provides a lower bound for
physician costs and conservatively estimates cost savings.
(2) The economic evaluation used a linear model to study
mean costs and effects. This enabled us to address the key
policymaking question of interest to decision makers,
which concerns the absolute change in effects per change
in costs conferred by the intervention. Linear regression
models may result in incorrect standard errors. While our
bivariate multilevel linear models account for clustering
and bivariate correlations at hospital and individual levels,
the use of Markov chain Monte Carlo methods to gener-
ate joint posterior distributions of incremental costs and
effects yielded sample means and estimates of uncertainty
robust to skewed costs [17, 28]. The main trial analysis ap-
propriately modelled caesarean sections as binary, and its
results, presented on the odds ratio scale, should be con-
sidered the definitive estimates of intervention impact [6].
(3) The central limit theorem, upon which valid inference
of sample means is based, may not hold with small sample
sizes [29]. Our dataset has 105,351 patients from 32
independent clusters with a median cluster size of 2644
patients (range: 638 to 9608). (4) Sample size calculations
for the QUARISMA trial were not designed to test cost-
effectiveness hypotheses. Methodological guidance suggests
that economic evaluation should focus on characterizing
differences between study group, rather than formal hy-
pothesis testing [21]. This trial had a large sample size, and
overall and stratified cost-effectiveness analyses were able
to detect a difference between study groups at a signifi-
cance level of 0.05, suggesting that the sample size was ad-
equate. (5) Our analysis was based on a health system
perspective. Patients and providers may have personal pref-
erences for caesarean sections, positive or negative, not
Table 2 Changes in per-patient costs due to the intervention, by clinical categorya, b
Cost component BMLM (crude) BMLM (adjusted)
Coef. (ß) ($) Std. Err. ($) 95% CI ($) P value Coef. (ß) ($) Std. Err. ($) 95% CI ($) P valuec
All participants (N = 105,351 patients; 32 hospitals)
Delivery (caesarean or vaginal)d −8.3 8.2 (−24.4 to 7.7) 0.310 −6.2 7.7 (−21.3 to 9.0) 0.424
Maternal complicationse 19.9 30.0 (−38.9 to 78.8) 0.507 16.3 29.9 (−42.3 to 74.8) 0.586
Neonatal complicationsf −196 33.8 (−262 to −130) <0.001 −190 33.3 (−255 to −125) <0.001
Low-risk group (N = 49,281 patients; 32 hospitals)
Delivery (caesarean or vaginal)d −17.2 9.4 (−35.7 to 1.3) 0.069 −22.0 9.0 (−39.5 to −4.5) 0.014
Maternal complicationse 22.0 38.4 (−53.2 to 97.2) 0.566 14.7 38.1 (−59.9 to 89.3) 0.700
Neonatal complicationsf −215 42.0 (−297 to −133) <0.001 −219 41.8 (−301 to −137) <0.001
High-risk group (N = 56,070 patients; 32 hospitals)
Delivery (caesarean or vaginal)d 17.6 12.2 (−6.3 to 41.6) 0.149 14.8 12.2 (−9.0 to 38.7) 0.223
Maternal complicationse 17.6 45.3 (−71.2 to 106) 0.698 14.2 45.1 (−74.3 to 103) 0.753
Neonatal complicationsf −136 51.2 (−237 to −36.0) 0.008 −126 50.0 (−224 to −27.6) 0.012
BMLM bivariate multilevel linear model, CI confidence interval
aModel coefficients (ß), standard errors, and 95% confidence intervals present costs given in 2013 Canadian dollars = (0.94 USD) [30]
bTotal costs calculated using CIHI National Physician Database 2011–2012 physician fees for the Province of Quebec [13]
cThe P value is the probability of observing a result at least as extreme as the z-statistic, for the null hypothesis that the difference in the rate changes in costs for
the intervention group from baseline to post-intervention versus the control group from baseline to post-intervention does not differ from zero
dDelivery costs include: caesarean delivery (primary or secondary, with or without induction, with or without uterine scar, pediatric or adult); vaginal delivery (with
or without anaesthetic, with or without intervention, assisted or unassisted, pediatric or adult)
eMaternal complication costs include: maternal death, hysterectomy, symptomatic uterine rupture, thromboembolic disease, internal organ injuries, perineal tear
(grades 3–4), puerperal infection/sepsis, postpartum hospital stay ≥7 days, admission to intensive care unit, readmission to hospital after postpartum discharge,
blood transfusion
fNeonatal complication costs include: intrapartum/neonatal death, Apgar score (<4; 4–7), major and minor acidosis (pH <7; pH 7–7.1), major and minor trauma,
intraventricular haemorrhage, seizure at less than 24 h, invasive and non-invasive mechanical ventilation, necrotizing enterocolitis, hypoxic-ischaemic encephalopathy,
cardiopulmonary morbidity, neonatal infection/sepsis, blood transfusion
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captured by this analysis. (6) The main trial analysis identi-
fied a possible random increase in complications in the
control group. Some proportion of the cost savings con-
ferred by the intervention might be attributable to random
variation; this cannot be ascertained from the trial data. (7)
Hospitals eligible for inclusion in this trial had a minimum
annual delivery volume of 300; intervention performance
in smaller hospitals is unknown, and this may affect the
scope for achieving benefits at scale. Returns from the
QUARISMA trial itself may range from $0.5 million to $5
million in the 1-year post-intervention period alone
(Additional file 1: Table S10). (8) This study was done
in a single jurisdiction; differences in health system
organization and financing may limit transferability of
results to other settings. A national budget impact
analysis is being conducted to translate these results
for all Canadian provinces. (9) The relatively short
trial time horizon does not elucidate how the inter-
vention impact may evolve over time.
A similar program could be beneficial in other regions
with similar or higher caesarean section rates [6]. Cost-
effectiveness results can be adapted to other jurisdictions
by adjusting for local baseline caesarean rates, health sys-
tem costs, and proportions of high- and low-risk patients.
Conclusions
From a healthcare payer perspective, a multifaceted
intervention involving audits and feedback resulted in a
small reduction in caesarean deliveries and an important
reduction in per-patient costs. These results were
achieved without increasing neonatal and maternal mor-
bidity and mortality.
In keeping with the theory of change for the QUAR-
ISMA intervention, which attempted to optimize med-
ical practice by reducing unnecessary caesareans, our
study found that women with low-risk pregnancies expe-
rienced statistically significant reductions in caesarean
sections and costs, while changes for the high-risk sub-
group were not significant. We also found evidence of
improved quality along the continuum of care. Cost re-
ductions were driven principally by lower rates of neo-
natal complications and corresponding lower use of
resources within the intervention group. These changes
are consistent with improvements in the quality of care
in intervention group hospitals.
Findings from our study provide critical new evidence
concerning a safe and possibly sustainable strategy to re-
duce unnecessary caesarean sections and shed new light
on the potential for audit and feedback interventions to
improve quality of care while controlling costs. Delivery
of the intervention at wider scale accompanied by fur-
ther research is required to assess whether the improve-
ments in clinical practice driving reductions in caesarean
sections and cost savings are sustainable over time.
Additional file
Additional file 1: Supplementary material for a cluster-randomized trial
to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis.
(PDF 716 kb)
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